All News

Your daily dose of the clinical news you may have missed.

Highlights from AAD 2025: Experts share updates on systemic therapy for atopic dermatitis, pediatric rashes, and contact dermatitis for PCPs.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

Your daily dose of the clinical news you may have missed.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.

Your daily dose of the clinical news you may have missed.

New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.

The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.

The model identified BMI, tobacco use, and family history of CRC as the strongest predictors for advanced neoplasia in young adults.

In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.

Your daily dose of the clinical news you may have missed.

The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.

The number of lung cancer deaths averted represents more than 51% of the expected reduction in total cancer deaths, researchers reported.

Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.